Vitamin C and COVID-19: should clinical trials be prioritised for low income settings and vitamin C-deficient populations?
Keyword(s):
Low Cost
◽
TO THE EDITOR: Managing coronavirus disease 2019 (COVID-19) in resource-limited settings requires a number of considerations, including reducing or preventing requirements for respiratory support.1 Vitamin C is a low cost, readily available therapy that the World Health Organization has highlighted for further research as an adjunctive intervention with biological plausibility for improving the clinical outcome of patients with COVID-19